Logo

Cepheid

Danaher Agrees to Provide Cepheid Tuberculosis Test to Global Fund at Cost

The tuberculosis test cartridges will be offered at $7.97 each to the Global Fund and less-developed countries eligible for Cepheid's Global Access Program.

Cepheid Nabs CE-IVD Mark for Molecular NPM1 Mutation Test for AML Monitoring

The test quantifies mutant NPM1 mRNA transcripts in peripheral blood specimens from patients with acute myeloid leukemia.

People in the News at Invitae, Cepheid, Nucleai, Angle, Quantum-Si, Twist Bioscience

Executive and academic appointments, promotions, and departures in omics and molecular diagnostics for the week of May 22, 2023.

Danaher Business Shifts as COVID-19 Revenues Continue to Decline
Premium

The firm saw total revenues decrease 7 percent, with core revenues down 4 percent and base business core revenue growth of 6 percent.

Cepheid Preparing New Infectious Disease Test Launches in 2023, Beyond
Premium

The firm's planned launches include a respiratory virus panel, a gastrointestinal panel, and a fingerstick tuberculosis test, it revelaed this week at ECCMID.

Mar 10, 2023

BioMérieux, Biocartis, Beckman Coulter Gain FDA 510(k) Clearances in February

Feb 13, 2023

Boston University, Cepheid Get FDA EUAs for COVID-19, Monkeypox Tests

Jan 24, 2023

Danaher Q4 Revenues Rise 3 Percent Despite Difficulties in China

Nov 18, 2022

New Products Posted to GenomeWeb: Foundation Medicine, Cepheid, Thermo Fisher, Olink, More

Nov 7, 2022

Cepheid Nabs CE Mark for Group B Strep Test

Oct 20, 2022

Danaher Q3 Revenues Rise 6 Percent as Businesses Step Back From COVID-19 Products

Jul 25, 2022

Highly Anticipated Cepheid Omni Point-of-Care System Falls Off Radar
Premium

Jul 21, 2022

Danaher Cites Diversified Business, Core Growth, Sustained China Sales as Drivers of Strong Q2
Premium

Jun 27, 2022

Cepheid, BioGX to Jointly Develop Monkeypox PCR Test for GeneXpert System

May 19, 2022

Cepheid Gets CE Mark for Updated Rapid COVID MDx Test

May 12, 2022

Cepheid Adds New Gene Target to SARS-CoV-2 Molecular Test to Account for Variants

May 2, 2022

Top Five Articles on GenomeWeb Last Week: Illumina, Janssen Biotech, Cepheid, More

Apr 25, 2022

Cepheid Developing Xpert Test to Distinguish Between Bacterial, Viral Infections
Premium

Jan 27, 2022

Danaher Q4 Revenues Rise 21 Percent

Jan 14, 2022

In Brief This Week: BGI, Gencove, Cepheid, Biocartis, Biognosys, Co-Diagnostics, More

Oct 21, 2021

Cepheid Sees High Demand for Respiratory Tests Through Remainder of 2021
Premium

Oct 14, 2021

Cepheid Obtains CE Mark for Expanded Combo COVID Test

Sep 14, 2021

Updated Cepheid SARS-CoV-2, Flu, RSV Test Nabs FDA EUA

Jul 30, 2021

Cepheid Gets $28M From BARDA for SARS-CoV-2 Tests

Jul 29, 2021

Cepheid Nabs CE Mark for PCR-Based HIV-1 Tests

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.